Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation
- PMID: 10542298
- DOI: 10.1074/jbc.274.45.32512
Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation
Abstract
Hypercholesterolemia-induced vascular disease and atherosclerosis are characterized by a decrease in the bioavailability of endothelium-derived nitric oxide. Endothelial nitric-oxide synthase (eNOS) associates with caveolae and is directly regulated by the caveola protein, caveolin. In the present study, we examined the effects of oxidized low density lipoprotein (oxLDL) on the subcellular location of eNOS, on eNOS activation, and on caveola cholesterol in endothelial cells. We found that treatment with 10 microgram/ml oxLDL for 60 min caused greater than 90% of eNOS and caveolin to leave caveolae. Treatment with oxLDL also inhibited acetylcholine-induced activation of eNOS but not prostacyclin production. oxLDL did not affect total cellular eNOS abundance. Oxidized LDL also did not affect the palmitoylation, myristoylation or phosphorylation of eNOS. Oxidized LDL, but not native LDL, or HDL depleted caveolae of cholesterol by serving as an acceptor for cholesterol. Cyclodextrin also depleted caveolae of cholesterol and caused eNOS and caveolin to translocate from caveolae. Furthermore, removal of oxLDL allowed eNOS and caveolin to return to caveolae. We conclude that oxLDL-induced depletion of caveola cholesterol causes eNOS to leave caveolae and inhibits acetylcholine-induced activation of the enzyme. This process may be an important mechanism in the early pathogenesis of atherosclerosis.
Similar articles
-
Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis.J Physiol. 2003 Feb 15;547(Pt 1):21-33. doi: 10.1113/jphysiol.2002.031534. Epub 2003 Jan 10. J Physiol. 2003. PMID: 12562964 Free PMC article. Review.
-
High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae.J Biol Chem. 2000 Apr 14;275(15):11278-83. doi: 10.1074/jbc.275.15.11278. J Biol Chem. 2000. PMID: 10753938
-
Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase.J Biol Chem. 2001 Apr 27;276(17):14212-21. doi: 10.1074/jbc.M007659200. Epub 2001 Jan 22. J Biol Chem. 2001. PMID: 11278358
-
Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae.J Biol Chem. 2004 Nov 19;279(47):48794-800. doi: 10.1074/jbc.M313897200. Epub 2004 Sep 20. J Biol Chem. 2004. PMID: 15383526
-
Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease.Trends Cardiovasc Med. 2001 Aug;11(6):246-50. doi: 10.1016/s1050-1738(01)00119-0. Trends Cardiovasc Med. 2001. PMID: 11673056 Review.
Cited by
-
Hypertension in chronic kidney disease: What lies behind the scene.Front Pharmacol. 2022 Oct 11;13:949260. doi: 10.3389/fphar.2022.949260. eCollection 2022. Front Pharmacol. 2022. PMID: 36304157 Free PMC article. Review.
-
LOX-1: Regulation, Signaling and Its Role in Atherosclerosis.Antioxidants (Basel). 2019 Jul 11;8(7):218. doi: 10.3390/antiox8070218. Antioxidants (Basel). 2019. PMID: 31336709 Free PMC article. Review.
-
Emerging Roles of Vascular Endothelium in Metabolic Homeostasis.Circ Res. 2018 Aug 3;123(4):477-494. doi: 10.1161/CIRCRESAHA.118.313237. Circ Res. 2018. PMID: 30355249 Free PMC article. Review.
-
Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis.J Physiol. 2003 Feb 15;547(Pt 1):21-33. doi: 10.1113/jphysiol.2002.031534. Epub 2003 Jan 10. J Physiol. 2003. PMID: 12562964 Free PMC article. Review.
-
Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits.Naunyn Schmiedebergs Arch Pharmacol. 2014 May;387(5):433-44. doi: 10.1007/s00210-014-0958-4. Epub 2014 Feb 5. Naunyn Schmiedebergs Arch Pharmacol. 2014. PMID: 24496478
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources